| Original language | English (US) |
|---|---|
| Pages (from-to) | 256-257 |
| Number of pages | 2 |
| Journal | Infectious Diseases in Clinical Practice |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2004 |
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
A 48-week duration of therapy with pegylated interferon a2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus
John G. Bartlett
Research output: Contribution to journal › Article › peer-review